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Tumour suppressors: A developing role for p53?
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An increasing body of evidence indicates that p53, the
product of a tumour suppressor gene, has a role in
development — could this developmental role have
provided the primary driving force in the evolution of a
protein best known as a stress–response integrator?
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The incidence of most tumours progressively increases
from nearly zero in childhood to a high level in old age.
The rate of increase is rapid, typically being proportional
to the fifth or sixth power of age. Hence most tumours
affect individuals outside their reproductive prime. Until
relatively recently, the age structure of human populations
was quite different from the ageing populations now seen
in the developed world. Indeed, the 29 year increase in
life expectancy in the USA since 1900 is about the same as
the increase in life expectancy seen in the 5000 years prior
to 1900 [1]. 
Thus the prevalence of cancer in human populations is
certainly a feature of the modern epoch. Animals in the
wild are subject to predation, disease and competition,
and so the usual age structure is such that young animals
greatly outnumber old. The observed incidence of neo-
plasms in wild animals will be lower than expected, as sick
tumour-bearing animals will tend quickly to be eaten by
predators. Despite this ascertainment bias, and while neo-
plasms are seen in a wide range of animals (including
diverse invertebrates), they are in general rare in non-
human animals.
The rarity of tumours in young, reproductively-competent
animals requires explanation. This might be a con-
sequence of both the time-dependent accumulation of
carcinogenic exposure and also the need for multiple
genetic events to occur. However, the existence of a range
of genetic syndromes in which neoplasms occur in early
life — such as xeroderma pigmentosa, familial adenoma-
tous polyposis and ataxia telangiectasia — argues that a
strong selective pressure exists for the evolution of
systems that prevent neoplasia. The absence of genes that
play a part in the prevention of neoplasia leads to
increased tumour incidence — hence their classification as
‘tumour suppressor’ genes.
Studies of ‘knockout’ mice, in which specific genes have
been inactivated by targeted recombination, indicate that
some tumour suppressor genes, such as Retinoblastoma
(Rb), are clearly essential for development, whereas
others, such as those whose products are involved in the
mismatch repair of damaged DNA, are not. Some of these
genes clearly exert true tumour-suppressive effects, while
others act by preventing the accumulation of somatic
mutation, the molecular substrate for neoplasia. But may
there be alternative — or complementary — explanations
for the existence of such genes? In particular, is this ‘sup-
pression of neoplasia’ model sufficient, or even necessary,
to account for the evolution of the tumour-suppression
pathway that involves the well-known p53 protein?
Having once been a curiosity of tumour virologists and a
rather unusual ‘oncogene’, there is now no doubt that p53
acts in mammals as a potent tumour suppressor, and that
abnormalities of the p53 gene that inactivate the p53
pathway are critical steps in a majority of human and
rodent tumours. The currently prevalent model of p53
function is as a central integrator of stress-induced adap-
tive cell responses [2,3]. Stabilization and activation of p53
protein occurs not only after genotoxic insult, but after a
diverse range of other cellular stresses, such as the
deregulation of microtubule assembly, detachment of cells
from their normal substrate, addition or withdrawal of
cytokines and growth factors, hypoxia and cell ageing.
Activated p53 can then elicit, via both its sequence-
specific DNA-binding properties and other poorly under-
stood properties, a range of adaptive responses that
include growth arrest and apoptosis. By these means, p53
acts as a tumour suppressor. It is generally held that this is
the primary function of p53, but it is rarely considered how
this could be selected for by evolution, given that the
tumours in which p53 abnormalities occur are diseases of
late or post-reproductive life. Recent studies suggest a
more fundamental role for p53, not as a tumour suppressor,
but as a teratological suppressor.
The recognition of p53 as a tumour suppressor gene in the
late 1980s and speculations about its possible role in cell-
cycle control led to the view that p53 would turn out to be
an essential element in mammalian cells. In addition, the
earlier observations of developmentally regulated p53
expression [4–6] suggested that p53 may have a role in
development. However, the demonstration by Donehower
et al. [7] in 1992 that p53 null mice are viable quickly led to
the view that p53 is entirely dispensable for normal devel-
opment. Recently, more detailed analyses have shown that
a substantial fraction of p53 null mice do in fact have
significant developmental abnormalities, including pro-
found neural-tube defects associated with overgrowth of
neural tissue, and the affected embryos frequently
undergo resorption [8,9]. This is manifest as smaller litter
size with a relative deficiency of females. Furthermore,
recent observations indicate that p53 has a role in neuronal
differentiation [10,11], and the developing nervous system
is the only site in which p53 protein can be detected
during mouse development [12]. In this situation, paradox-
ically, it is a fall in p53 levels that is associated with differ-
entiation and concomitant cell-cycle exit. This suggests
that p53 has yet-undiscovered functions over and above its
role in the induction of apoptosis and growth arrest.
The over-expression of wild-type p53 protein, in trans-
genic mice and other systems, has been shown to be
detrimental to normal development. The forced over-
expression of wild-type p53 during mouse development
has proved difficult, but recently Godley et al. [13] suc-
ceeded and found that there were profound alterations of
renal development. Earlier studies of p53 over-expression
in the lens [14] and in Xenopus oocytes [15] also showed
that development was disrupted, suggesting that too much
p53 protein is not compatible with normal development.
Adult mammalian tissues contain very low levels of p53
protein and show considerable heterogeneity in the induc-
tion of the p53 pathway by ionizing radiation. This pattern
is set up in development from a situation where all cells
respond by turning on the p53 pathway and the down-
stream events, and there is a progressive restriction in the
response during embryonic and fetal life [12]. 
Lutzker and Levine [16] have recently reported that
teratocarcinoma cells have high levels of transcriptionally
inactive p53 protein, which diminishes on differentiation
of the cells in this in vitro system (paralleling the impor-
tant observations of Rogel et al. [4] and Louis et al. [5]).
Finally, the importance of p53 in development is empha-
sized by the dramatic rescue of early embryonic lethality
in mdm2 null mice by deletion of p53 — the implication is
that the MDM2 protein, known to form a complex with
p53, is a critical negative regulator of p53, and the lethality
of the mdm2 null mutants is due to overactivation of the
p53 pathway [17,18]. Taken together, these data suggest
that the level of p53 protein expression has to be very
carefully controlled in development. While normal devel-
opment can occur in the absence of p53, there is a signifi-
cant risk of embryonic or fetal loss [8,9], and, in addition,
too much p53 can be harmful during normal develop-
mental processes [13–15]. What, then, is the role of p53
during development?
Two important papers [19,20] indicate that p53 can act as
a teratological suppressor, in that the presence of a func-
tional p53 pathway reduces the amount of defective
embryos/foetuses after exposure to drugs or radiation: in
the absence of functional p53, there is a big increase in
‘embryopathy’. Nicol et al. [19] found that there was a 2–4-
fold increase in the embryotoxicity and teratogenicity of
the environmental teratogen benzo[a]pyrene in p53 null
animals compared with wild-type controls. They went on
to show that there was 3.6-fold increase in the fetal resorp-
tion of homozygous p53–/– mice, with heterozygous p53+/–
mice having an intermediate level of resorption.
Norimura et al. [20] reported similar observations in mice
exposed to X-irradiation in utero. In p53 null mice irradi-
ated with 2 Gy of X rays, there was a 70% incidence of
anomalies and 7% incidence of deaths. In contrast, in wild-
type mice there was the reverse relationship of abnor-
malities and death — 20% versus 60%. Again, the hetero-
zygous mice had an intermediate phenotype, indicating a
gene-dosage effect similar to that observed previously for
p53-mediated apoptosis. These observations suggest that
p53 has a critical role in mammalian development — the
sensing and elimination, probably by apoptosis, of
damaged cells. The role for p53-dependent apoptosis as a
regulator in development is further substantiated by the
observations of Wubah et al. [21] on teratogen-induced eye
defects. Animals are, of course, naturally exposed to a
wide range of potential teratogens — this is emphasized
by the well-known very high rate of spontaneous abortion
in the outbred human population [1].
Taken together, these observations and ideas give a
radically new perspective on the role and evolution of p53.
It is now clear that p53 has as its primary function the
coordination of multicellular adaptive responses to diverse
environmental stresses [2,3]. During development, the
effective response to such stresses is of critical importance
in determining successful reproductive strategies. p53 has
a critical role in development, with its function manifest as
a teratological suppressor [19,20], and we speculate that
this may indeed have been the primary drive in its evolu-
tion, with the role in neoplasia being a secondary — very
important, but still secondary — property.
To test such an idea will require the study of more diverse
representatives of phylogeny than mice and humans. The
important idea, however, is that the development of
embryos in higher metazoa is regulative and requires con-
siderable plasticity, which the adaptive p53 response can
help provide. The emergence of p53 as an adaptive-
response regulator may have been a key permissive step in
the evolution of developmental complexity, facilitating
the remarkable cellular plasticity seen in higher metazoa
and in vertebrates in particular. It makes good biological
sense for there to be a mechanism allowing vertebrates to
delete ‘defective’ cells, so that other, normal cell pop-
ulations can ‘fill’ the gaps. The use of p53 as a tumour
suppressor would be a useful additional attribute, par-
ticularly in those complex vertebrates with complex
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arrangements of renewing cell hierarchies which are
exposed to environmental stresses.
What is known about the evolution of p53? Soussi and
May [22] have recently reviewed this topic and empha-
sized the important conservation in a range of vertebrates,
including mammals, birds, amphibians and fish, of certain
regions of p53 — in particular, the transcriptional activ-
ation domain and regions of the sequence-specific DNA-
binding domain. The sequences between these regions
show considerable divergence. Recently, some sequences
from clam and squid have been reported that show simi-
larities to conserved regions of vertebrate p53. Although
these sequences are related to vertebrate p53, there can
be no certainty regarding the biological function(s) of
these putative p53 homologues. 
No p53 homologues are apparent in the genome of the
budding yeast Saccharomyces cerevisiae, and none has yet
been reported in the fruitfly Drosophila or the nematode
Caenorhabditis elegans. More work needs to be done on
this, but the currently available data raise the possibility
that p53 appeared relatively late in evolution, and the
exact phylogenetic origin of p53 is a critical question. Raff
[23] has defined a number of key regulatory events and
related them to metazoan phylogeny (Fig. 1). It may be
that the emergence of tissues the development of which
necessarily involves competition between cellular popu-
lations required the existence of a control gene such as
p53 early in phylogeny. Alternatively, p53 may have
appeared later to provide a better response to adverse
external stimuli. Identifying when p53 functions emerged
in phylogeny should help resolve these issues. 
In conclusion, we speculate that p53 has a primary role as
the ‘guardian of the babies’, coordinating the adaptive
responses to cellular stress of many forms and acting pri-
marily as a teratological suppressor, with a secondary role
in neoplasia. This is clearly a heterodox view, but one that
should stimulate debate and provide a new perspective for
further research, particularly in defining the functional
significance of the p53 pathway in phylogeny. Was the
emergence of p53 a critical step in the development of
metazoa? This would link development, evolution, stress
responses and neoplasia in a unique way.
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Figure 1
A number of critical innovations underpin the
evolution of metazoa [23]. The p53 gene has
been well defined only in higher chordates,
though it may exist in molluscs [22]. A critical
issue for the future will be to define how the
diverse adaptive responses mediated through
the p53 pathway have evolved; this should
cast light on the speculation that p53 has
manifestly contributed to the evolution of
development. (Adapted from [23].)
Porifera
1      Multicellularity
2      Tissues
3      A–P axis
4      Hox gene expression
5      Metameric segmentation
6      Pentameral symmetry
7      Neural crest and Hox
        gene amplification
Cnideria
Ctenophora
Platyhelminthes
Molluscs
Annelids
Brachiopods
Sipunculida
Arthropods
Echinoderms
Hemichordates
Chordates
1
2
3
4
5
6
7
© 1997 Current Biology
5. Louis JM, McFarland VW, May P, Mora TP: The phosphoprotein p53
is down-regulated post-transcriptionally during embryogenesis
during vertebrate development. Biochim Biophys Acta 1988,
950:395–402. 
6. Schmid P, Lorenz A, Hameister H, Montenarh M: Expression of p53
during mouse embryogenesis. Development 1991, 113:857–865.
7. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA,
Butel JS, Bradley A: Mice deficient for p53 are developmentally
normal but susceptible to spontaneous tumours. Nature 1992,
356:215–221.
8. Armstrong J, Kaufman MH, Harrison DJ, Clarke AR: High frequency
developmental abnormalities in p53-deficient mice. Curr Biol
1995, 5:931–936.
9. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T: A
subset of p53-deficient embryos exhibit exencephaly. Nat Genet
1995, 10:175–180.
10. Feirrera A, Kosic KS: Accelerated neuronal differentiation induced
by p53 suppression. J Cell Sci 1996, 109:1509–1516.
11. Eizenberg O, Faberelman A, Gottlieb E, Oren M, Rotter V, Schwartz
M: p53 plays a regulatory role in differentiation and apoptosis of
central nervous system-associated cells.  Mol Cell Biol 1996,
16:5178–5185.
12. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper
A, Walsh FS, Wright EG, Balmain A, Lane DP, Hall PA: The p53
response to ionising radiation in adult and developing murine
tissues. Oncogene 1996, 12:2575–2587.
13. Godley LA, Kopp JB, Eckhaus M, Paglino JJ, Owens J, Varmus HE:
Wild-type p53 transgenic mice exhibit altered differentiation of
the ureteric bud and possess small kidneys. Genes Dev 1996,
10:836–850.
14. Nakamura T, Pichel JG, Williams Simons L, Westphal H: An
apoptotic defect in lens differentiation caused by human p53 is
rescued by a mutant allele. Proc Natl Acad Sci USA 1995,
92:612–6146.
15. Hoever M, Clement JH, Wedlich D, Montenarh M, Kochel W: Over-
expression of wild-type p53 interferes with normal development
in Xenopus laevis embryos. Oncogene 1994, 9:109–120.
16. Lutzker SG, Levine AJ: A functionally inactive p53 protein in
teratocarcinoma cells is activated by either DNA damage or
cellular differentiation. Nat Med 1996, 2:804–810.
17. de Oca Luna RM, Wagner DS, Lozano G: Rescue of early
embryonic lethality in mdm2-deficient mice by deletion of p53.
Nature 1995, 378:203–206.
18. Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embryonic
lethality in mdm2-deficient mice by absence of p53. Nature 1995,
378:206–208.
19. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wells PG: A
teratologic suppressor role for p53 in benzo[a]pyrene-treated
p53-deficient mice. Nat Genet 1995, 10:181–187.
20. Norimura T, Nomoto S, Katsuki M, Gondo Y, Kondo S: p53-
dependent apoptosis suppresses radiation-induced
teratogenesis. Nat Med 1996, 2:577–580.
21. Wubah JA, Ibrahim MM, Gao X, Nguyen D, Pisano MM, Knudsen TB:
Teratogen-induced eye defects mediated by p53-dependent
apoptosis. Curr Biol 1996, 6:60–69.
22. Soussi T, May P: Structural aspects of the p53 protein in relation
to gene evolution: a second look. J Mol Biol 1996, 260:623–637.
23. Raff RA: The Shape of Life. Chicago: University of Chicago Press;
1996.
Dispatch R147
If you found this dispatch interesting, you might also want
to read the February 1997 issue of
Current Opinion in
Genetics & Development
which included the following reviews, edited
by James R. Broach and Arnold J. Levine,
on Oncogenes and cell proliferation:
Phosphorylation and proteolysis: partners in the
regulation of cell division in budding yeast
R.J. Deshaies
Cdks and the Drosophila cell cycle
P.J. Follette and P.H. O’Farrell
Stopping and starting the meiotic cell cycle
A.W. Page and T.L. Orr-Weaver
CDKs and cyclins in transition(s)
R.P. Fisher
Retinoblastoma protein in growth suppression and
death protection
J.Y.J. Wang
p53; from inductive signal to cellular effect
R. Hansen and M. Oren
Bcl-2 and the ICE family of apoptotic regulators:
making a connection
L. Rao and E. White
Pheromone signalling and polarized morphogenesis 
in yeast
E. Leberer, D.Y. Thomas and M. Whiteway
MEKKs, GCKs, MLKs, PAKs, TAKs, and Tpls: upstream
regulators of the c-Jun amino-terminal kinases?
G.R. Fanger, P. Gerwins, C. Widman, M.B. Jarpe 
and G.L. Johnson
Signal transduction from multiple Ras effectors
M.E. Katz and F. McCormick
Novel mechanisms of RTK signal generation
F.U. Weiss, H. Daub and A. Ullrich
DCC’s function takes shape in the nervous system
P.A. Kolodziej
Control of cell cycle arrest by the Mec1sc/Rad3sp DNA
structure checkpoint pathway
A.M. Carr
Tying loose ends: roles of Ku and DNA-dependent
protein kinase in the repair of double-strand breaks
M.R. Lieber, U. Grawunder, X. Wu and M. Yaneva
MutS homologs in mammalian cells
R. Fishel and T. Wilson
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